Articles tagged with: ASCO 2012 Meeting
Researchers from France have found that myelodysplastic syndromes patients receiving Vidaza at any time before stem cell transplantation may achieve similar outcomes as patients treated with conventional chemotherapy.
However, they also found that patients who had received both chemotherapy and Vidaza (azacitidine) at some point prior to stem cell transplantation had worse survival compared to patients who received chemotherapy or Vidaza alone.
Based on their findings, the researchers conclude that Vidaza alone may be a valid treatment to reduce the disease burden before stem cell transplantation, the only potential …
French researchers have found that adding anti-thymocyte globulin to the preparative treatment for stem cell transplantation may improve outcomes for myelodysplastic syndromes patients.
Specifically, patients treated with anti-thymocyte globulin (ATG) during preparative treatment experienced significantly fewer cases of acute graft-versus-host disease, a common transplant-related complication in which donor immune cells recognize the recipient’s cells as foreign and attack them.
These results were presented earlier this month at the American Society of Clinical Oncology’s annual meeting in Chicago.
Stem cell transplantation is currently the only potential cure for myelodysplastic syndromes (MDS). …
Myelodysplastic syndromes patients with autoimmune disorders may be more responsive to treatment with Vidaza or Dacogen than patients without autoimmune disorders, according to results from a recent retrospective analysis.
However, the investigators point out that further studies are needed to confirm their findings and to better understand how the two drugs work in patients with autoimmune disorders.
The findings were presented during a poster session at the 2012 annual meeting of the American Society of Hematology (ASCO) in Chicago earlier this month.
Previous research has suggested that the development of …
Results from a recent Phase 1 study show that Revlimid in combination with Velcade may be effective and safe in myelodysplastic syndromes.
Specifically, 28 percent of myelodysplastic syndromes (MDS) patients responded to the combination treatment. In addition, patients receiving the highest tested dosage of Velcade (bortezomib) did not experience any dose-limiting side effects.
Based on their findings, the study investigators concluded that the combination will be tested further in patients with advanced MDS and acute myeloid leukemia (AML).
These findings were presented at the 2012 annual meeting of the American …
Elderly patients with myelodysplastic syndromes or acute myeloid leukemia may experience long-term survival after undergoing stem cell transplantation, according to a recent study conducted at the MD Anderson Cancer Center in Houston.
Although a number of patients experienced long-term disease control, many patients still relapsed or died from transplant-related causes. The study investigators acknowledge that new treatment approaches are needed to resolve the number of relapses and deaths associated with transplantation.
The findings were presented in a poster session at the American Society of Clinical Oncology (ASCO) 2012 meeting in …